NCT02671435 2025-07-22
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
MedImmune LLC
Phase 1/2 Active not recruiting
MedImmune LLC
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
University of Pittsburgh
Eli Lilly and Company
Merck KGaA, Darmstadt, Germany